about
HCMV pUL135 remodels the actin cytoskeleton to impair immune recognition of infected cells.Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.Immunology of human papillomavirus infection in lower genital tract neoplasia.CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemiaDendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R).Human cellular immune responses against human papillomaviruses in cervical neoplasia.CD8(+) T-cell recognition of a synthetic epitope formed by t-butyl modificationCervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology.Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemiaCD8+ T-cell specificity is compromised at a defined MHCI/CD8 affinity threshold.Decreased HPV-specific T cell responses and accumulation of immunosuppressive influences in oropharyngeal cancer patients following radical therapy.A novel tumor antigen derived from enhanced degradation of bax protein in human cancers.HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells.HPV16 E6 29-38-specific T cells kill cervical carcinoma cells despite partial evasion of T-cell effector function.The nature of telomere fusion and a definition of the critical telomere length in human cells.Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women.T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells.Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.Systemic listeriosis following vaccination with the attenuated Listeria monocytogenes therapeutic vaccine, ADXS11-001Individual variation in the frequency of HLA class II-specific cytotoxic T lymphocyte precursors.Expression of CD200 on AML blasts directly suppresses memory T-cell function.Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells.A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression.Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.Promiscuous behavior of HPV16E6 specific T cell receptor beta chains hampers functional expression in TCR transgenic T cells, which can be restored in part by genetic modification.Human cancer vaccinesSensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human PapillomavirusT-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancerCytotoxic T cells head for the clinic?The use of human leucocyte antigen class I transgenic mice to investigate human immune functionAnti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID miceActivated B cells mediate efficient expansion of rare antigen-specific T cellsDefinition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic miceThe immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapseIncreased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLLChronic lymphocytic leukaemia: the role of T cells in a B cell disease
P50
Q34116205-BE45EABF-D998-45F7-A0B6-A818A214C1C2Q34189203-D146B4AF-10CF-4373-8027-DFE3ED15127EQ34374027-19A98A81-DDC8-481D-9CA4-3609CC55C62EQ34977414-41F68789-D9EF-4362-B133-E061E067CD05Q35047009-B0E9CCAB-CD21-4F7E-97E1-D180D501C677Q35571065-EDF01D3A-9741-460D-BD84-1E09439C7D4EQ36019759-55A6308D-9B3F-4D82-8CAD-194D171B6ED8Q36615509-6441CB77-4207-4160-98F1-68BDA694BFF5Q37118775-8B82CB75-5220-4ACC-897B-B7EF6975DF51Q37560213-6C715965-2F7C-4745-84FE-B3209DE08A77Q39328588-A1B69378-250C-4C51-94CA-F3E643EB90B3Q39520036-0DAAB64F-3402-4391-9847-868BA6EA9DEAQ39660191-23D46233-94E0-49E1-A956-042F8354EDCDQ39998541-238E77E9-3301-4790-BCD0-915C341E3580Q40073766-8AF79672-A0E8-4FE0-A853-C676D94B1C07Q40148614-16A59B01-976A-4A8B-ACF1-A5189C07395AQ40336672-EE36CAA4-90E8-4238-A822-8CD0F933B6D9Q40478974-0B6B27AC-5042-48E0-B153-A6D4AF7C4254Q41619256-FE1FBAFB-B708-4437-924A-68BF0E9C986AQ41739364-B54F2DA5-9D3F-4B8A-899A-50B2CCBF4813Q42572899-6BD27195-FFC4-43E9-B187-3ACC0EF32472Q42572959-8ADDC482-B881-4FCB-99E3-F39866769A15Q45769906-C2213E10-0D34-4EF8-8761-544E8B133FA4Q47637442-C4F6AC5D-972A-48C0-B44D-A8A736303F06Q48956742-B32B530C-FD2F-4FD3-A15B-E030599DCFB1Q50977009-0C097A10-D8E4-4049-AC11-3B7B0C8BCFEAQ51107636-AA1B37C4-1336-44E8-974F-FB10AA38A291Q55031696-B3866FB0-1C05-442D-BEA6-BE2704340E89Q60193081-0E1B2BB1-3713-4F3F-8B7C-EFC722BBA182Q60302619-F39E835A-49BA-4632-9F0C-0B4EB7D13879Q61700525-6864F95D-63E0-4F46-8F69-8F5E1FB35C0DQ73621950-555CCECF-6983-4913-BFDD-B9198A0C251CQ77813558-1E808741-752D-4135-86FB-64553C4D904DQ77839439-46D34D41-44D0-4CEB-B033-CEDAA82CDDA8Q79829633-F4002FFA-2023-48D3-A994-E1EEA42CE54FQ81624591-9E52769A-C994-49F3-ADA8-743B9198693BQ86883798-4EFC8204-ECC1-4B52-B7BA-A72AE6B12CB9Q91183940-D1B30E00-8667-42AA-A6C0-229CDC26AF52Q92837570-95A1AF4E-1F91-4C04-87C0-FEBC9C4231D4
P50
description
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Stephen Man
@ast
Stephen Man
@en
Stephen Man
@es
Stephen Man
@nl
Stephen Man
@sl
type
label
Stephen Man
@ast
Stephen Man
@en
Stephen Man
@es
Stephen Man
@nl
Stephen Man
@sl
prefLabel
Stephen Man
@ast
Stephen Man
@en
Stephen Man
@es
Stephen Man
@nl
Stephen Man
@sl
P214
P106
P21
P214
P31
P496
0000-0001-9103-1686
P735
P7859
lccn-no2007074177